BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22225955)

  • 1. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι.
    Sajan MP; Nimal S; Mastorides S; Acevedo-Duncan M; Kahn CR; Fields AP; Braun U; Leitges M; Farese RV
    Metabolism; 2012 Apr; 61(4):459-69. PubMed ID: 22225955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.
    Farese RV; Sajan MP; Yang H; Li P; Mastorides S; Gower WR; Nimal S; Choi CS; Kim S; Shulman GI; Kahn CR; Braun U; Leitges M
    J Clin Invest; 2007 Aug; 117(8):2289-301. PubMed ID: 17641777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin signalling in hepatocytes of humans with type 2 diabetes: excessive production and activity of protein kinase C-ι (PKC-ι) and dependent processes and reversal by PKC-ι inhibitors.
    Sajan MP; Farese RV
    Diabetologia; 2012 May; 55(5):1446-57. PubMed ID: 22349071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.
    Sajan MP; Ivey RA; Farese RV
    Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity.
    Sajan MP; Standaert ML; Nimal S; Varanasi U; Pastoor T; Mastorides S; Braun U; Leitges M; Farese RV
    J Lipid Res; 2009 Jun; 50(6):1133-45. PubMed ID: 19202134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
    Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
    Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical protein kinase C in cardiometabolic abnormalities.
    Farese RV; Sajan MP
    Curr Opin Lipidol; 2012 Jun; 23(3):175-181. PubMed ID: 22449812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKCλ haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes.
    Sajan MP; Ivey RA; Lee M; Mastorides S; Jurczak MJ; Samuels VT; Shulman GI; Braun U; Leitges M; Farese RV
    Mol Endocrinol; 2014 Jul; 28(7):1097-107. PubMed ID: 24877563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.
    Sajan MP; Ivey RA; Lee MC; Farese RV
    J Lipid Res; 2015 Jan; 56(1):70-80. PubMed ID: 25395359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin action in human hepatocytes: coactivation of atypical protein kinase C alters 5'-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression.
    Sajan MP; Ivey RA; Farese RV
    Diabetologia; 2013 Nov; 56(11):2507-16. PubMed ID: 23933835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ
    Sajan MP; Hansen BC; Higgs MG; Kahn CR; Braun U; Leitges M; Park CR; Diamond DM; Farese RV
    Neurobiol Aging; 2018 Jan; 61():225-237. PubMed ID: 29032894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC.
    Sajan MP; Bandyopadhyay G; Miura A; Standaert ML; Nimal S; Longnus SL; Van Obberghen E; Hainault I; Foufelle F; Kahn R; Braun U; Leitges M; Farese RV
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E179-92. PubMed ID: 19887597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.
    Farese RV; Sajan MP; Standaert ML
    Exp Biol Med (Maywood); 2005 Oct; 230(9):593-605. PubMed ID: 16179727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical PKC: a target for treating insulin-resistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Farese RV; Lee MC; Sajan MP
    Expert Opin Ther Targets; 2014 Oct; 18(10):1163-75. PubMed ID: 25213731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
    Sajan MP; Standaert ML; Rivas J; Miura A; Kanoh Y; Soto J; Taniguchi CM; Kahn CR; Farese RV
    Diabetologia; 2009 Jun; 52(6):1197-207. PubMed ID: 19357831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity.
    Sajan MP; Acevedo-Duncan ME; Standaert ML; Ivey RA; Lee M; Farese RV
    Diabetes; 2014 Aug; 63(8):2690-701. PubMed ID: 24705403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota.
    Standaert ML; Ortmeyer HK; Sajan MP; Kanoh Y; Bandyopadhyay G; Hansen BC; Farese RV
    Diabetes; 2002 Oct; 51(10):2936-43. PubMed ID: 12351430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B.
    Sajan MP; Leitges M; Park C; Diamond DM; Wu J; Hansen BC; Duncan MA; Apostolatos CA; Apostolatos AH; Kindy M; Farese RV
    Curr Alzheimer Res; 2021; 18(12):941-955. PubMed ID: 34951366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status.
    Farese RV; Sajan MP
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E385-94. PubMed ID: 19996389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.